The US Food and Drug Administration has approved Nulojix (belatacept), a new treatment to prevent organ rejection in adult patients who have had a kidney transplant. The developer is Bristol-Myers Squibb Company. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
